InvestorsHub Logo
Followers 74
Posts 15839
Boards Moderated 0
Alias Born 04/26/2010

Re: louieblouie post# 338368

Tuesday, 05/04/2021 6:35:55 PM

Tuesday, May 04, 2021 6:35:55 PM

Post# of 424150

even accepting Amarin’s allegations as true, coverage for the Hikma generic is
only approximately one-fourth of the total volume of Amarin’s brand product.



They're admitting infringement right there! SHTG indication is 9% of total sales, and they're claiming it's 25%.


Amarin alleges Health Net induces infringement by listing Amarin’s brand drug
product on a lower tier and offering more favorable payment terms for the generic product despite knowing others purportedly use the generic product to infringe.



What does "others who are infringing" have to do with anything? This is about HN specifically covering GV for R-IT via it's PA form.


Any evidence purportedly showing a pharmacist is induced by the pharmacy plan would contradict evidence other sources (e.g, the prescription, Hikma’s label, or Hikma’s press releases) encouraged the pharmacist’s infringement.



Bullshit - there's no contradiction at all - HN is encouraging the pharmacist to infringe by covering GV for R-IT uses via it's formulary and PA.

The Thought Police: To censor and protect. Craig Bruce

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News